Pharmaceutical Industry in China - Cutting-Edge Analysis of Multinational and Chinese Pharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges
LONDON, Nov. 27, 2014 /PRNewswire/ -- "Pharmaceutical Industry China – Cutting-Edge Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges" provides you with a detailed investigation of the market size, segmentation, key players, SWOT analysis, influential Government policies, and business and economic environments. The report is supported by over 199 tables & figures within 153 pages. The Chinese biopharmaceutical market is presented as follows:
• By Company (e.g., AMOYTOP BIOTECH, BEIJING CONTINENT PHARMACEUTICALS, FUSOGEN, SHANGHAI HUAGUAN BIOCHIP, SIBIONO GENETECH, ABBOTT, ROCHE, PFIZER, GSK, NOVARTIS)
• By Therapeutic Area (e.g., Anti-infective, Cancer, Diabetes, Dementia, Depression)
A wealth of financial information is provided including:
• Company financials, sales & revenue figures – historical to Q2•2013
• China GDP, economic growth, export (bulk drug, formulations) figures
• Indian health expenditure as a function of GDP
• Growth change figures of emerging and developing countries (India, Russia, China, Brazil)
• Economic growth figures of advanced economies (USA, UK, Germany, France, Italy, Spain, Japan, Canada)
• Projected figures of strategic emerging industry GDP percentage contribution
SWOT, Economic and Business Environment specifics include:
• Key strengths, weaknesses and threats influencing leading player position within the market
• Top Five Contract Pharmaceutical Export Markets of China
• Major players within China's leading therapeutic markets (e.g., cancer, allergy, liver disease)
• Multinational penetration into the Chinese Pharma Market
• Comprehensive product portfolios, R&D activity and pipeline therapeutics
• M&A activity and future strategies of top Chinese pharmacos
• Economic indicators, trade policy, merchandise and commercial trade statistics
• Gross Domestic Product of China, historic and projection analysis
• Chinese economic outlook in comparison to advanced economies
• Three Tier 'Pharmerging' Markets with Potential for Significant Growth
• Prescription drug sales distribution channels in China
• Major biogeneric products in China
This report highlights a number of significant Chinese and multinational pharmacos and gives details of their operations, products, financials and business strategy.
• Amoytop Biotech
• Active Pharmaceutical Products
• Beijing Continent Pharmaceuticals
• FusoGen Pharmaceuticals
• Shanghai Huaguan Biochip
• SiBiono GeneTech
• Abbott
• AstraZeneca
• Boehringer Ingelheim
• Eli Lilly
• GlaxoSmithKline
• Johnson & Johnson Medical
• Merck
• Novartis
• Pfizer
• Roche
Forecast projections and future growth rates are provided to give you a forthcoming perspective of this growing industry. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed.
What you will gain:
• An in-depth understanding of the Chinese biopharmaceutical market and it's environment
• Current market facts, figures and product lines of key players in the industry
• An insight into how generic therapeutics will propagate the Chinese biopharmaceutical market
• Knowledge of how the Chinese pharma market will integrate into the global healthcare market
• Information on key regulatory and government policies
• Data on levels of private and publically funded biopharma studies in China
• Strategies on how to adapt and restructure current business models to this industry
This report tackles key concerns to the Chinese biopharmaceutical market such as:
• Lack of regulatory policy and legislation
• Reimbursement schemes and payers concerns
• Funding and government sponsorship issues
• International scepticism of Chinese safety and efficacy therapeutic profiles
This report will tell you if the companies mentioned are:
• Strong, competitive players
• Pooling their resources for specific growth and therapeutic areas
• Investing strategically in R&D
• Have a history of strategic M&A activity
Benefits of Investing in our Cutting-Edge Reports: Clients receive complementary content* with mid-level and enterprise wide licences Post-sale complementary consultation with senior expert analyst is included Use of tables and figures in your own reports and presentations is permitted Each report provides straight-talking strategic analysis & sector intelligence All reports are updated each quarter to give you the most up-to-date information WE WANT TO MAXIMIZE YOUR BUSINESS POTENTIAL * Subject to terms & conditions negotiated with Kelly Scientific Publications prior to sale
Download the full report: https://www.reportbuyer.com/product/1859471/
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pharmaceutical-industry-in-china---cutting-edge-analysis-of-multinational-and-chinese-pharma-companies-industry-trends-environment-regulation-market-drivers-restraints-opportunities--challenges-300002087.html
SOURCE ReportBuyer
Share this article